Table 3.
Baseline characteristics and clinical outcome for IgAN by glomerular immune deposit location
| Mesangium + PCWs | Mesangium only | P-value | |
|---|---|---|---|
| [n = 21 (26%)] | [n = 59 (74%)] | ||
| Clinical characteristics | |||
| Age (years) | 36 (25–43) | 37 (25–45) | 0.793 |
| Gender | 0.598 | ||
| Female | 43% (9) | 34% (20) | |
| Male | 57% (12) | 66% (39) | |
| Race | 0.929 | ||
| Asian | 14% (3) | 13% (8) | |
| Caucasian | 71% (15) | 68% (40) | |
| Other | 14% (3) | 19% (11) | |
| SCr at biopsy (mg/dL) | 1.3 (0.99–3.35) | 1.3 (0.95–2.50) | 0.768 |
| eGFR at biopsya (mL/min/1.73 m2) | 67.4 (29.7–79.3) | 52.8 (27.6–92.1) | 0.756 |
| uPCR at biopsy (g/g) | 3.35 (0.93–5.5) | 1.05 (0.6–2.01) | 0.025 |
| uPCR at biopsyb | 0.780 | ||
| High | 24% (5) | 31% (18) | |
| Low | 76% (16) | 69% (41) | |
| Length of follow-up (months) | 21 (12.2–35.3) | 33 (14.7–57.5) | 0.059 |
| Biopsy characteristics | |||
| Mesangial hypercellularity (M1) | 65% (13) | 72% (42) | 0.576 |
| Endocapillary hypercellularity (E1) | 55% (11) | 38% (22) | 0.201 |
| Segmental sclerosis (S1) | 75% (15) | 74% (43) | 1.000 |
| Interstitial fibrosis (T) | 0.409 | ||
| T0 | 55% (11) | 50% (29) | |
| T1 | 15% (3) | 29% (17) | |
| T2 | 30% (6) | 21% (12) | |
| Presence of crescents/segmental glomerular necrosis | 48% (10) | 22% (13) | 0.047 |
| Treatment | |||
| Use of ACEi or ARB | 80% (16) | 90% (52) | 0.267 |
| Use of prednisone and/or cytotoxic agents | 45% (9) | 41% (23) | 0.796 |
| Use of fish oil | 40% (8) | 39% (22) | 1.000 |
| Outcome | |||
| Number of patients reaching combined outcomec | 48% (10) | 24% (14) | 0.026 |
| eGFR at follow-upa (mL/min/1.73 m2) | 65.9 (9.0–93.9) | 64.9 (29.4–96.4) | 0.767 |
| uPCR at follow up (g/g) | 0.50 (0.16–1.60) | 0.45 (0.1–1.0) | 0.433 |
| uPCR at follow upb | 1.000 | ||
| High | 31% (4) | 29% (12) | |
| Low | 69% (9) | 71% (30) | |
| Slope of eGFRa (mL/min/1.73 m2)/month | −0.50 ± 2.66 | 0.09 ± 1.20 | 0.225 |
Values are presented as median (interquartile range) and percentage and absolute numbers.
a
eGFR based of a total of 65 patients with follow-up and removal of outliers; slope of eGFR: change of eGFR over the observation period.
b
High is defined as a uPCR ≥1; low is defined as a uPCR <1.
c
Combined outcome: doubling of SCr concentration, renal replacement therapy, kidney transplantation or death.